M
Michael J. Birrer
Researcher at University of Arkansas for Medical Sciences
Publications - 579
Citations - 64433
Michael J. Birrer is an academic researcher from University of Arkansas for Medical Sciences. The author has contributed to research in topics: Ovarian cancer & Cancer. The author has an hindex of 102, co-authored 554 publications receiving 54218 citations. Previous affiliations of Michael J. Birrer include University of Texas MD Anderson Cancer Center & University of Arkansas at Little Rock.
Papers
More filters
Proceedings ArticleDOI
Abstract CT092: Pharmacokinetics of a THIOMABTMantibody drug conjugate (TDC): DMUC4064A in a phase 1 study with platinum-resistant ovarian cancer
Amit Garg,Gaohong She,Ian Donatello,Matts Kågedal,Douglas D. Leipold,Ola Saad,Joyce F. Liu,Kathleen N. Moore,Erika Hamilton,Howard A. Burris,Judy Wang,Michael J. Birrer,Eric W. Humke,Sandhya Girish +13 more
TL;DR: This is the first report of clinical PK data of a TDC demonstrating slower clearance compared to a conventional ADC format, and a clear correlation of acMMAE with tAb exposure was observed.
Journal ArticleDOI
An evaluation of survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: A Gynecologic Oncology Group experience.
TL;DR: OCCC were significantly younger, more often of Asian race, stage I, good PS, and optimally surgically debulked than SOC patients, and had better PFS and OS due to better prognostic factors prior to adjustment.
Proceedings ArticleDOI
18/#499 Mirvetuximab soravtansine and carboplatin for treatment of patients with recurrent folate receptor alpha-positive platinum-sensitive ovarian cancer: a final analysis
Kathleen N. Moore,David M. O'Malley,Ignace Vergote,Lainie P. Martin,Antonio González-Martín,Jiuzhou Wang,Michael Method,Michael J. Birrer +7 more
TL;DR: In this article , the efficacy and safety of Mirvetuximab soravtansine (MIRV) and carboplatin (carbo) were evaluated in patients with recurrent FRα-positive platinum sensitive ovarian cancer (PSOC) measured by immunohistochemistry.
Patent
Methods and systems for treatment of ovarian cancer
TL;DR: In this paper, the authors identify gene signatures which permit the identification of patients who will benefit from cytoreductive surgery as treatment for ovarian cancer and provide methods of treatment, assays, and systems relating to ovarian cancer.
Journal ArticleDOI
Corrigendum to "Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG oncology study (NRG-GY008)" [Gynecol. Oncol. Rep. 31 (2020) 100532].
Alessandro D. Santin,Virginia L. Filiaci,Stefania Bellone,Roisin E. O'Cearbhaill,Elena Ratner,Cara Mathews,Guilherme Cantuaria,Camille C. Gunderson,Teresa Rutledge,Barbara M. Buttin,Heather A. Lankes,Michael J. Birrer +11 more
TL;DR: This research presents a novel probabilistic approach to estimating the response of the immune system to laser-spot assisted, 3D image analysis of central nervous system injury.